SCHEMBL6487678

SCHEMBL6487678

CS(=O)(=O)OCc1cc(Cl)ccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.39
IDO1 P14902 2/20 0.38
POLB P06746 1/20 0.37
ADRA1D P25100 2/20 0.37
ADRA1A P35348 2/20 0.37
ADRA1B P35368 2/20 0.37
FLT1 P17948 2/20 0.37
FLT4 P35916 2/20 0.37
KDR P35968 2/20 0.37
MAOB P27338 1/20 0.37
DBH P09172 1/20 0.36
HTR2A P28223 1/20 0.36
SLC6A4 P31645 1/20 0.36
KCNH2 Q12809 1/20 0.36
ALDH1A1 P00352 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TP53 P04637 1/20 0.35
DDR1 Q08345 2/20 0.35
ALKBH1 Q13686 1/20 0.35
SCN5A Q14524 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16550662 0.86 IDO1 (0.55) IDO1ALDH1A1L3MBTL1
SCHEMBL15413757 0.84 PSEN1 (0.41) TRPV4ADRA1DADRA1AADRA1BHTR2A
SCHEMBL27535882 0.83 SLC6A4 (0.41) ADRA1DADRA1AADRA1BHTR2ASLC6A4
SCHEMBL2521711 0.83 HTR2A (0.38) FLT1FLT4KDRHTR2ASLC6A4
SCHEMBL29220297 0.83 IDO1 (0.40) IDO1POLBSCN9A
SCHEMBL15054089 0.83 ADRA1D (0.38) TRPV4POLBADRA1DADRA1AADRA1B
SCHEMBL2548023 0.83 NOS3 (0.38) TRPV4IDO1FLT1FLT4KDR
SCHEMBL15415062 0.81 TRPV4 (0.50) TRPV4POLBALDH1A1L3MBTL1TP53
SCHEMBL5957680 0.79 PTGER1 (0.41) HTR2ATP53
SCHEMBL7020172 0.79 HSD17B10 (0.50) FLT1FLT4KDRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC 2018-06-21 US disclosed
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 TRPV4 4863/4885IDO1 3541/4885POLB 36/4885
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD TRPV4 1720/4885IDO1 2471/4885POLB 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.